Long-acting amylin analogue that enhances satiety; often paired with semaglutide (CagriSema) for additive fat loss.
Cagrilintide is a long-acting analogue of amylin — a hormone co-secreted with insulin that signals fullness, slows gastric emptying, and reduces food intake. It works through a different pathway than GLP-1 drugs, which is the whole point of it.
Because the mechanisms are complementary, cagrilintide is most often studied alongside semaglutide in a combination called CagriSema, where the two together produce greater weight loss than either alone. On its own it still drives meaningful appetite reduction.
It is an emerging compound — promising but with a thinner long-term safety record than the established GLP-1 agonists. It is dosed once weekly.
Amylin-driven satiety that complements GLP-1 mechanisms.
Phase 2: meaningful standalone weight loss
Paired with semaglutide (CagriSema) for additive fat loss beyond a GLP-1 alone.
CagriSema trials show enhanced weight reduction
We rate every peptide honestly across four dimensions — and tell you what it's not.
Evidence Profile
Promising amylin analogue with positive phase 2 data, strongest when combined with semaglutide (CagriSema); still pre-approval.
Promising but early. Strong animal data and/or small/preliminary human studies, not yet confirmed in robust trials.
Controlled trials & clinical data in people
Phase 2 monotherapy and CagriSema combination data are positive; phase 3 ongoing.
Preclinical results in animal models
Amylin-pathway preclinical support for satiety effects.
How plausibly it works at a biological level
Amylin-receptor agonism is a well-defined, complementary satiety mechanism.
Depth of documented safety in humans
Tolerability consistent with incretin-class GI effects; long-term data limited.
Men already on a GLP-1 who want an additive satiety effect, or those exploring a non-GLP-1 mechanism
Usually combined with a GLP-1 — titrate each compound independently. Emerging compound; weigh the thinner long-term safety data.
Women seeking additional appetite control alongside a GLP-1
Avoid in pregnancy and while breastfeeding. Limited female-specific data — proceed conservatively and discuss with a clinician.
Limited female-specific data; avoid in pregnancy and while breastfeeding.
This section is always free and never locked.
Discontinue for severe or persistent GI symptoms.
Often stacked with a GLP-1 — titrate each compound independently.
Emerging compound with limited long-term safety data.
The effects most commonly reported with Cagrilintide, when they tend to show up, and how to manage them.
Eat smaller, lower-fat meals; titrate slowly; it usually fades within 1–2 weeks at a stable dose.
Hydrate well, add fiber, stay active. Tell your clinician if severe or persistent.
Prioritize protein and don't under-eat — rapid loss can cost muscle. Lift weights.
Rotate sites; let alcohol dry fully before injecting.
Stop immediately and seek medical care — this is a red-flag symptom.
Individual responses vary. Stop and consult a clinician for severe, persistent, or unexpected reactions.
14 steps with photos, pro tips, and a dosing calculator.
Unlock Full Guide7 days free. Then $24/month.
████████ ████
████████ ████
████████ ████
Dosing info requires Core or Pro
Unlock DosingAlways free. Never locked.
A preview of the member outcomes dashboard. Real, anonymized Cagrilintide results populate here as the community logs data.
See aggregated results from real users — benefit ratings, common goals, side effect frequency, and more.
Unlock with Core or ProGet the complete step-by-step guide, personalized dosing, and daily tracking.
View Full GuidePepCompass provides educational information only. Nothing on this platform constitutes medical advice, diagnosis, or treatment. All content is for informational and research purposes only. Always consult a licensed healthcare provider before starting any peptide protocol. Individual results vary.